Neuland Labs.

Neuland Labs positioned FY25 as a year of consolidation, with total income declining by 4.7% to ₹1,497.3 crores. The fourth quarter was particularly weak, with revenue down 14% YoY to ₹335.8 crores and EBITDA margin contracting significantly to 17.3%. Management attributed the decline to the 'natural life cycle' of certain products that contributed in FY24 but not at the same level in FY25, stating this was an expected outcome. Despite the profit decline, the company generated a strong free cash flow of ₹111 crores for the year and ended with a net cash position of ₹29 crores.

Management expressed optimism for a growth recovery in FY26. They guided for the growth trajectory to resume based on the higher revenue of FY24, effectively bypassing the weaker FY25 performance. Key drivers include the new production block at Unit 3 starting commercial production, a molecule commercialized in FY25 beginning to contribute, and another new CMS molecule expected to be commercialized in FY26. Management anticipates that the CMS business will be the primary growth engine compared to the GDS segment.

The Custom Manufacturing Solutions (CMS) business recorded revenues of approximately ₹637 crores in FY25. Management highlighted a 'snowballing' effect in their CDMO business, driven by a growing reputation, focused business development, and favorable macro factors (geopolitical shifts). The company is seeing higher quality opportunities and has established expertise in niche areas like deuterated chemistry and peptides, with 10-15 peptide projects currently in the pipeline. The new molecule set for FY26 commercialization is a high-volume, second-source contract in the COPD segment, signaling a move towards larger, more stable projects.

While expecting revenues to rebound, management was very cautious on margins. They described FY25 margins as 'suboptimal' and expect them to improve with operating leverage in FY26. However, they repeatedly warned that the highly favorable margins of FY24 were a 'North Star' and not a new baseline. This cautious stance is part of a broader policy of not providing quantitative guidance, which management acknowledged frustrates investors but is necessary due to the confidential and inherently volatile nature of their project-based business.

The company invested ₹26.4 crores in capital expenditure during the year, primarily towards the new production block in Unit 3 which is now capitalized. The focus on cash generation was evident, with working capital at 107 days of sales. Neuland also paid back ₹39.4 crores of term loan debt. The significant INR 300-350 crore capex announced previously for large-scale peptide manufacturing capabilities at Unit 1 is proceeding, underscoring the company's strategic focus on this high-growth area.